Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 8/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | WNT3A | P56704 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15188473 | 0.89 | ALDH1A1 (0.50) | KDM4EATMGSK3BMAPTALDH1A1 | |
| SCHEMBL15188478 | 0.89 | ALDH1A1 (0.54) | KDM4EATMGSK3BMAPTALDH1A1 | |
| SCHEMBL881622 | 0.86 | KDM4E (0.41) | KDM4EATMGSK3BMAPTALDH1A1 | |
| SCHEMBL627847 | 0.83 | ATM (0.70) | KDM4EATMMAPTALDH1A1TP53 | |
| SCHEMBL15188476 | 0.80 | PTPN1 (0.49) | GSK3B | |
| SCHEMBL15188490 | 0.79 | PTPN1 (0.41) | ATMGSK3BHPGDPKMTSHR | |
| SCHEMBL16343663 | 0.79 | PTGS1 (0.41) | ATMGSK3BHPGDPKMTSHR | |
| SCHEMBL881325 | 0.79 | KDM4E (0.78) | KDM4EATMMAPTL3MBTL1HPGD | |
| SCHEMBL2985748 | 0.78 | ALDH1A1 (0.68) | KDM4EATMMAPTALDH1A1TP53 | |
| SCHEMBL1183664 | 0.76 | ATM (0.47) | KDM4EATMGSK3BMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822520-B2 | Substituted bicyclic HCV inhibitors | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822520-B2 | Substituted bicyclic HCV inhibitors | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130178507-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178507-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2012040389-A2 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120028978-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028978-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010111673-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178507-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | HAVCR2, LIPC, EIF2AK2 | KDM4E 3798/4885ATM 3633/4885GSK3B 558/4885 |
| US-20120028978-A1 | SUBSTITUTED BICYCLIC HCV INHIBITORS | HAVCR2, LIPC, EIF2AK2 | KDM4E 3798/4885ATM 3633/4885GSK3B 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.